Skip to main content
. 2025 May 17;16:4608. doi: 10.1038/s41467-025-59865-1

Table 2.

Treatment Response by p16 Status in the Evaluable Cohort

HPV status (p16) pCR (n,%) MPR (n,%) PPR (n,%) Total patients (n)
Positive 5 (55.6%) 3 (33.3%) 1 (11.1%) 9
Negative 9 (64.3%) 2 (14.3%) 3 (21.4%) 14